|Bid||135.57 x 0|
|Ask||135.58 x 0|
|Day's Range||129.60 - 137.52|
|52 Week Range||61.00 - 188.28|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||106.76|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||0.24 (0.18%)|
|Ex-Dividend Date||Jun 04, 2020|
|1y Target Est||102.86|
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
Because of that and the fact that cash is flowing into this sector due to the pandemic, life sciences campuses are hot commodities these days among real estate investors. A real estate fund managed by Brookfield is selling a best-in-class, 2.3 million-square-foot portfolio of lab office buildings to a fund managed by Blackstone for $3.45 billion. It enabled Brookfield to realize some of the value of its investment in Forest City Realty Trust.
WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has received the 2020 Global Customer Value Leadership Award from Frost & Sullivan, a global business research and consulting firm. This marks the fourth consecutive year WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.